Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anselamimab - Caelum Biosciences

Next Previous
Drug Profile

Anselamimab - Caelum Biosciences

Alternative Names: 11-1F4; CAEL-101; Ch mAb 11-1F4; Chimeric fibril reactive monoclonal antibody 11-1F4 -Caelum Biosciences; Fibril-reactive monoclonal antibody 11-1F4; mAb 11-1F4

Latest Information Update: 24 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University
  • Developer Alexion AstraZeneca Rare Disease; Caelum Biosciences
  • Class Monoclonal antibodies
  • Mechanism of Action Serum amyloid A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis; Amyloid light-chain amyloidosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Amyloid light-chain amyloidosis

Most Recent Events

  • 02 Jun 2026 Adverse events and efficacy data from the phase III trials in Amyloid light-chain amyloidosis presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 29 May 2026 Updated efficacy data from the phase III CARES trials in Amyloid light-chain amyloidosis released by AstraZeneca
  • 29 May 2026 Stanford University plans a phase 0 trial for Amyloid light-chain amyloidosis in USA in July 2026 (IV, Infusion) (NCT07615270)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top